Elaprase
Regenxbio’s investigational gene therapy shows promise in Hunter syndrome
The rare genetic disease is estimated to affect one in every 100,000 to 170,000 births
Takeda to sell Japan consumer health unit for $2.3bn
Deal helps to reduce debt accrued from Shire takeover
Takeda’s subcutaneous Entyvio formulation faces FDA rejection
Was seeking approval in moderate-to-severe ulcerative colitis
Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
First wave of new molecular entities has potential to generate 14 approvals
Takeda divests over-the-counter and prescription drugs to Stada for $660m
Japanese pharma said it has plans to divest $10bn in non-core assests
Takeda offloads select portfolio to Acino ahead of Shire takeover
Hopes to reduce debt before acquistion completion
Shire bags US approval for constipation drug Motegrity
Approval is boost as Takeda takeover nears completion
Takeda secures investor backing for £46bn Shire takeover
The deal is expected to close early next year
Shire’s angioedema drug Takhzyro claims EU approval
Approval shortly follows a green light in the US
Shire’s angioedema drug Takhzyro recommended in Europe
Analysts expect the drug to make around $1.8bn in peak sales
Shire’s bleeding disorder drug approved in Europe
Veyvondi for patients with rare disease von Willebrand disease